Joshua N. Burton

Joshua N. Burton

Auto-generated profile, based on publicly available information

Joshua N. Burton

Base5 Genomics, Inc

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SGSante Gnerre
Sante Gnerre
IMIain MacCallum
Iain MacCallum
DPDariusz Przybylski
Dariusz Przybylski
FRFilipe J. Ribeiro
Filipe J. Ribeiro
JBJoshua N. Burton
Joshua N. Burton
DJDavid B. Jaffe
David B. Jaffe
Massively parallel DNA sequencing technologies are revolutionizing genomics by making it possible to generate billions of relatively short (~100-base) sequence reads at very low cost. Whereas such data can be readily used for a wide range of biomedical applications, it has proven difficult to use them to generate high-quality de novo genome assemblies of large, repeat-rich vertebrate genomes. To date, the genome assemblies generated from such data have fallen far short of those obtained with the older (but much more expensive) capillary-based sequencing approach. Here, we report the development of an algorithm for genome assembly, ALLPATHS-LG, and its application to massively parallel DNA sequence data from the human and mouse genomes, generated on the Illumina platform. The resulting draft genome assemblies have good accuracy, short-range contiguity, long-range connectivity, and coverage of the genome. In particular, the base accuracy is high (≥99.95%) and the scaffold sizes (N50 size = 11.5 Mb for human and 7.2 Mb for mouse) approach those obtained with capillary-based sequencing. The combination of improved sequencing technology and improved computational methods should now make it possible to increase dramatically the de novo sequencing of large genomes. The ALLPATHS-LG program is available at http://www.broadinstitute.org/science/programs/genome-biology/crd .

1 December 2013 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
JBJoshua N Burton
Joshua N Burton
AAAndrew Adey
Andrew Adey
RPRupali P Patwardhan
Rupali P Patwardhan
RQRuolan Qiu
Ruolan Qiu
JKJacob O Kitzman
Jacob O Kitzman
JSJay Shendure
Jay Shendure

7 August 2013 in Nature
Verified
Journal Article
Open access
PDF file
AAAndrew Adey
Andrew Adey
JBJoshua N. Burton
Joshua N. Burton
JKJacob O. Kitzman
Jacob O. Kitzman
JHJoseph B. Hiatt
Joseph B. Hiatt
ALAlexandra P. Lewis
Alexandra P. Lewis
JSJay Shendure
Jay Shendure
Haplotype-resolved whole-genome sequencing of the HeLa CCL-2 strain shows that HeLa is relatively stable in terms of point variation; integration of several data sets reveals strong, haplotype-specific activation of the proto-oncogene MYC by the human papilloma virus type 18 genome, and enables the relationship between gene dosage and expression to be examined. The first genomic characterization of the HeLa cancer cell line, the longest-serving and arguably most commonly used human cell line in biomedical research, reveals a genome that is surprisingly stable with respect to both point-mutation and copy-number alterations. The point-mutation rate may be no higher than the somatic mutation rate of normal tissue, and very few copy-number alterations distinguish the genomes of different HeLa strains that were split from one another in the mid-1950s. The authors examine the relationship between gene dosage and expression by integrating several data sets, including those from the ENCODE project, and find strong activation of the MYC proto-oncogene by the human papilloma virus type 18 (HPV-18) integration at chromosome 8q24.21. The HeLa cell line was established in 1951 from cervical cancer cells taken from a patient, Henrietta Lacks. This was the first successful attempt to immortalize human-derived cells in vitro1. The robust growth and unrestricted distribution of HeLa cells resulted in its broad adoption—both intentionally and through widespread cross-contamination2—and for the past 60 years it has served a role analogous to that of a model organism3. The cumulative impact of the HeLa cell line on research is demonstrated by its occurrence in more than 74,000 PubMed abstracts (approximately 0.3%). The genomic architecture of HeLa remains largely unexplored beyond its karyotype4, partly because like many cancers, its extensive aneuploidy renders such analyses challenging. We carried out haplotype-resolved whole-genome sequencing5 of the HeLa CCL-2 strain, examined point- and indel-mutation variations, mapped copy-number variations and loss of heterozygosity regions, and phased variants across full chromosome arms. We also investigated variation and copy-number profiles for HeLa S3 and eight additional strains. We find that HeLa is relatively stable in terms of point variation, with few new mutations accumulating after early passaging. Haplotype resolution facilitated reconstruction of an amplified, highly rearranged region of chromosome 8q24.21 at which integration of the human papilloma virus type 18 (HPV-18) genome occurred and that is likely to be the event that initiated tumorigenesis. We combined these maps with RNA-seq6 and ENCODE Project7 data sets to phase the HeLa epigenome. This revealed strong, haplotype-specific activation of the proto-oncogene MYC by the integrated HPV-18 genome approximately 500 kilobases upstream, and enabled global analyses of the relationship between gene dosage and expression. These data provide an extensively phased, high-quality reference genome for past and future experiments relying on HeLa, and demonstrate the value of haplotype resolution for characterizing cancer genomes and epigenomes.

24 February 2006 in Physical Review B
Verified
Journal Article
Closed access
PDF file
ADAleksandar Donev
Aleksandar Donev
JBJoshua Burton
Joshua Burton
FSFrank H. Stillinger
Frank H. Stillinger
STSalvatore Torquato
Salvatore Torquato
Previous Monte Carlo investigations by Wojciechowski et al. have found two unusual phases in two-dimensional systems of anisotropic hard particles: a tetratic phase of fourfold symmetry for hard squares [Comput. Methods Sci. Tech. 10, 235 (2004)], and a nonperiodic degenerate solid phase for hard-disk dimers [Phys. Rev. Lett. 66, 3168 (1991)]. In this work, we study a system of hard rectangles of aspect ratio two, i.e., hard-square dimers (or dominos), and demonstrate that it exhibits phases with both of these unusual properties. The liquid shows quasi-long-range tetratic order, with no nematic order. The solid phase we observe is a nonperiodic tetratic phase having the structure of a random tiling of the square lattice with dominos with the well-known degeneracy entropy 1.79kB per particle. Our simulations do not conclusively establish the thermodynamic stability of this orientationally disordered solid; however, there are strong indications that this phase is glassy. Our observations are consistent with a two-stage phase transition scenario developed by Kosterlitz and co-workers with two continuous phase transitions, the first from isotropic to tetratic liquid, and the second from tetratic liquid to solid. We obtain similar results with both a classical Monte Carlo method using true rectangles and a novel molecular dynamics algorithm employing rectangles with rounded corners.

1 October 2009 in Genome Biology
Verified
Journal Article
Open access
PDF file
IMIain MacCallum
Iain MacCallum
DPDariusz Przybylski
Dariusz Przybylski
SGSante Gnerre
Sante Gnerre
JBJoshua Burton
Joshua Burton
ISIlya Shlyakhter
Ilya Shlyakhter
DJDavid B Jaffe
David B Jaffe
We demonstrate that genome sequences approaching finished quality can be generated from short paired reads. Using 36 base (fragment) and 26 base (jumping) reads from five microbial genomes of varied GC composition and sizes up to 40 Mb, ALLPATHS2 generated assemblies with long, accurate contigs and scaffolds. Velvet and EULER-SR were less accurate. For example, for Escherichia coli, the fraction of 10-kb stretches that were perfect was 99.8% (ALLPATHS2), 68.7% (Velvet), and 42.1% (EULER-SR).

11 September 2013 in Aging Cell
Verified
Journal Article
Open access
PDF file
STSean D. Taylor
Sean D. Taylor
NENolan G. Ericson
Nolan G. Ericson
JBJoshua N. Burton
Joshua N. Burton
TPTomas A. Prolla
Tomas A. Prolla
JSJohn R. Silber
John R. Silber
JBJason H. Bielas
Jason H. Bielas
Summary: Due largely to the inability to accurately quantify and characterize de novo deletion events, the mechanisms underpinning the pathogenic expansion of mtDNA deletions in aging and neuromuscular disorders remain poorly understood. Here, we outline and validate a new tool termed ‘Digital Deletion Detection’ (3D) that allows for high‐resolution analysis of rare deletions occurring at frequencies as low as 1 × 10−8. 3D is a three‐step process that includes targeted enrichment for deletion‐bearing molecules, single‐molecule partitioning of genomes into thousands of droplets for direct quantification via droplet digital PCR, and breakpoint characterization using massively parallel sequencing. Using 3D, we interrogated over 8 billion mitochondrial genomes to analyze the age‐related dynamics of mtDNA deletions in human brain tissue. We demonstrate that the total deletion load increases with age, while the total number and diversity of unique deletions remain constant. Our data provide support for the hypothesis that expansion of pre‐existing mutations is the primary factor contributing to age‐related accumulation of mtDNA deletions.